Email ID
Password
Scrip   
Exchange rates and rabeprazole dull Eisai's first half
02 November 2009
Ian Haydock

Global sales of Eisai's top product, the Alzheimer's disease therapy Aricept (donepezil), edged up by 2% to ¥156.0 billion ($1.73 billion) in the first half, despite the effects of the strong yen on sales outside Japan.

Much of the growth for the acetylcholinesterase inhibitor came from...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36